{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=91",
    "query": {
      "intervention": "Injectable Placebo",
      "page": 91
    },
    "page_size": 10
  },
  "pagination": {
    "page": 91,
    "page_size": 10,
    "total_count": 4225,
    "total_pages": 423,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=92&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=90&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T00:54:43.931Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05164094",
      "title": "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epstein-Barr Virus Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1189",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "10 Years to 30 Years"
      },
      "enrollment_count": 867,
      "start_date": "2021-12-28",
      "completion_date": "2027-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 65,
      "location_summary": "Huntsville, Alabama • Anaheim, California • Colton, California + 56 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05164094"
    },
    {
      "nct_id": "NCT00433173",
      "title": "Insulin Sensitivity in Men With the Metabolic Syndrome",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "intravenous glucose tolerance test",
          "type": "PROCEDURE"
        },
        {
          "name": "testosterone",
          "type": "DRUG"
        },
        {
          "name": "anastrozole",
          "type": "DRUG"
        },
        {
          "name": "goserelin acetate implant",
          "type": "DRUG"
        },
        {
          "name": "aerobic capacity (VO2 Max)",
          "type": "PROCEDURE"
        },
        {
          "name": "MRI",
          "type": "PROCEDURE"
        },
        {
          "name": "muscle biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "measurement of resting metabolic rate (energy expenditure)",
          "type": "PROCEDURE"
        },
        {
          "name": "Dual energy x-ray absorptiometry",
          "type": "PROCEDURE"
        },
        {
          "name": "Fasting oral glucose tolerance test",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "50 Years to 75 Years · Male only"
      },
      "enrollment_count": 72,
      "start_date": "2006-05",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2010-03-02",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00433173"
    },
    {
      "nct_id": "NCT06592794",
      "title": "A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Gastroenteritis",
        "Norovirus Acute Gastroenteritis"
      ],
      "interventions": [
        {
          "name": "mRNA-1403",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37864,
      "start_date": "2024-09-24",
      "completion_date": "2027-02-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 184,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 136 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06592794"
    },
    {
      "nct_id": "NCT04452318",
      "title": "COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "REGN10933 + REGN10987",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Day and older"
      },
      "enrollment_count": 3303,
      "start_date": "2020-07-13",
      "completion_date": "2021-10-04",
      "has_results": true,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 132,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04452318"
    },
    {
      "nct_id": "NCT06515418",
      "title": "Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Oral Azelaprag (BGE-105)",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo for Azelaprag (BGE-105)",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioAge Labs, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2024-06-27",
      "completion_date": "2025-02-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 14,
      "location_summary": "Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06515418"
    },
    {
      "nct_id": "NCT07711418",
      "title": "A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate-to-Severe Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Rezpegaldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 510,
      "start_date": "2026-08-07",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Oxnard, California • Palmdale, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Palmdale",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07711418"
    },
    {
      "nct_id": "NCT02021968",
      "title": "Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "TetraVax-DV-TV003",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rDEN2∆30-7169",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-11",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-15",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02021968"
    },
    {
      "nct_id": "NCT03039790",
      "title": "Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Norovirus"
      ],
      "interventions": [
        {
          "name": "NoV Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 528,
      "start_date": "2017-02-21",
      "completion_date": "2021-07-22",
      "has_results": true,
      "last_update_posted_date": "2022-11-09",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03039790"
    },
    {
      "nct_id": "NCT01994291",
      "title": "A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Edema, Diabetic"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-04634817",
          "type": "DRUG"
        },
        {
          "name": "Masked Sham Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 199,
      "start_date": "2013-11",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-10-17",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01994291"
    },
    {
      "nct_id": "NCT06577090",
      "title": "Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Nimacimab injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nimacimab placebo injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "semaglutide injection",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Nimacimab 300 mg injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Skye Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 136,
      "start_date": "2024-08-22",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-11-08T00:54:43.931Z",
      "location_count": 16,
      "location_summary": "Anniston, Alabama • Walnut Creek, California • Waterbury, Connecticut + 13 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06577090"
    }
  ]
}